<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836705</url>
  </required_header>
  <id_info>
    <org_study_id>TES13519</org_study_id>
    <secondary_id>2012-005642-38</secondary_id>
    <secondary_id>U1111-1115-7323</secondary_id>
    <nct_id>NCT01836705</nct_id>
  </id_info>
  <brief_title>Effect of SAR302503 on ECG Activity in Patients With Solid Tumors</brief_title>
  <official_title>Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To assess the effect of SAR302503 (500 mg) administered as 14-day repeated doses on the&#xD;
      QTcF interval compared to 1-day placebo in patients with advanced solid tumors.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the effect of SAR302503 administered as 14-day repeated doses on heart rate&#xD;
           (HR), QT, QTcB, and QTcN, PR and QRS compared to placebo.&#xD;
&#xD;
        -  To assess the clinical and laboratory safety of SAR302503&#xD;
&#xD;
        -  To document the plasma concentrations of SAR302503 at the time of ECG investigation.&#xD;
&#xD;
        -  To explore the Pharmacokinetic/Pharmacodynamic relationship between SAR302503&#xD;
           concentration and QTcF&#xD;
&#xD;
        -  To explore antitumor activity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total 7-10 weeks if not progressing to Segment 2. Segment 2 will be additional in 28-day&#xD;
      cycles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTc Friderica (QTcF) parameter</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic parameters (Heart Rate)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic parameters (QT)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic parameters (QTcBazett)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic parameters (QTcN)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic parameters (PR interval)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiographic parameters (QRS interval)</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>16 or more days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>16 or more days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter: Cmax, AUC0-24, Tmax, Tmax, Ctrough</measure>
    <time_frame>16 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Neoplasm Malignant</condition>
  <arm_group>
    <arm_group_label>Single-sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR302503 Placebo (1 day)-SAR302503 (500 mg, oral, qd, 14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR302503 (TG101348)</intervention_name>
    <description>Pharmaceutical form:capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>Single-sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SAR302503</intervention_name>
    <description>Pharmaceutical form:capsule&#xD;
Route of administration: oral</description>
    <arm_group_label>Single-sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panolosetron</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Single-sequence</arm_group_label>
    <other_name>Aloxi®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
        - Histologically or cytologically confirmed advanced solid malignancy that is metastatic or&#xD;
        unresectable, and for which standard curative measures do not exist&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior history of torsades de pointe, or congenital long QT syndrome.&#xD;
&#xD;
          -  Conditions with screening ECG in which repolarization is difficult to interpret, or&#xD;
             showing significant abnormalities. This includes, but is not limited to: High degree&#xD;
             atrioventricular (AV) block, pacemaker, atrial fibrillation or flutter&#xD;
&#xD;
          -  Screening ECG with QTc B or QTc F ≥480 msec (within 8 days of Day-1)&#xD;
&#xD;
          -  Significant hypokalemia at screening (K+ &lt;3.5 mmol/L) (within 8 days of Day-1)&#xD;
&#xD;
          -  Significant hypomagnesemia at screening and inclusion (Mg++ &lt;0.7 mmol/L) (within 8&#xD;
             days of Day -1)&#xD;
&#xD;
          -  Patient receives (and cannot discontinue), or is scheduled to receive, a concomitant&#xD;
             treatment known to carry a risk of both QT prolongation and torsade de pointe for 2&#xD;
             weeks before Day 1 and for the duration of Segment 1&#xD;
&#xD;
          -  Absence of completion of all prior chemotherapy, biological therapy, hormonal therapy,&#xD;
             targeted non-cytotoxic therapy ≥3 weeks; and radiotherapy ≥2 weeks prior to inclusion.&#xD;
&#xD;
          -  Patients with uncontrolled brain metastases or primary brain tumor. Patients with&#xD;
             brain metastasis are considered eligible if the patient has not received radiation&#xD;
             therapy for brain metastasis within 2 weeks of enrollment and has been on a stable&#xD;
             dose of steroids for ≥ 2 weeks.&#xD;
&#xD;
          -  Participation in any study of an investigational agent (drug, biologic, device) within&#xD;
             30 days prior to initiation of study drug, unless during non-treatment phase.&#xD;
&#xD;
          -  Anticipation of need for a major surgical procedure or radiation therapy during the&#xD;
             study treatment.&#xD;
&#xD;
          -  Concurrent treatment in another clinical trial or with any other cancer therapy&#xD;
             including chemotherapy, biological therapy, hormonal therapy, radiotherapy,&#xD;
             chemoembolization, cryotherapy, targeted non-cytotoxic therapy or patients planning to&#xD;
             receive these treatments during the study.&#xD;
&#xD;
          -  Inadequate organ function as defined by:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;1.5 X 10^9/L&#xD;
&#xD;
          -  Platelet count &lt;100 X 10^9/L&#xD;
&#xD;
          -  Hemoglobin: &lt;9 g/dL&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 x the upper limit of normal (ULN)&#xD;
&#xD;
          -  Serum amylase or lipase &gt;1.5 x ULN&#xD;
&#xD;
          -  Total bilirubin &gt;1.5 x ULN&#xD;
&#xD;
          -  Aspartate aminotransferase or alanine aminotransferase ≥2.5 x ULN&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt;2 at study entry.&#xD;
&#xD;
          -  Uncontrolled congestive heart failure (New York Heart Association Classification 3 or&#xD;
             4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral&#xD;
             artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3&#xD;
             months prior to initiation of study drug.&#xD;
&#xD;
          -  Ongoing or recent history (within 3 months of Day 1 Segment 1) of clinically&#xD;
             significant dysrrhythmia.&#xD;
&#xD;
          -  Patients taking a beta blocker within 7 days to Day 1 Segment 1 and during Segment 1&#xD;
&#xD;
          -  Other concurrent serious illness or medical condition, including active infection or&#xD;
             HIV disease.&#xD;
&#xD;
          -  Patients with known active (acute or chronic) Hepatitis A, B, C, and hepatitis B and&#xD;
             or C carriers. Prior history of chronic liver disease.&#xD;
&#xD;
          -  Patients with history of partial or total gastrectomy, or, if in the opinion of the&#xD;
             investigator, have any other disorder that would inhibit absorption of oral&#xD;
             medications.&#xD;
&#xD;
          -  Any severe acute or chronic medical, neurological, or psychiatric condition or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration, may interfere with the informed consent process and/or&#xD;
             with compliance with the requirements of the study, or may interfere with&#xD;
             interpretation of study results and, in the Investigator's opinion, would make the&#xD;
             patient inappropriate for entry into this study.&#xD;
&#xD;
          -  Contra-indications for palonosetron.&#xD;
&#xD;
          -  Use of drugs or herbal agents known to be at least moderate inhibitors or inducers of&#xD;
             CYP3A4, sensitive CYP3A4 substrate, or CYP3A4 substrate with narrow therapeutic index,&#xD;
             within 2 weeks of Day 1 and during study.&#xD;
&#xD;
          -  Concomitant treatment with H2-blockers is not allowed within 7 days prior to Day 1&#xD;
             Segment 1 and during entire study.&#xD;
&#xD;
          -  Known hypersensitivity to any excipients in IMP formulations.&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Women of childbearing potential, unless using effective contraception (other than oral&#xD;
             contraceptives) while on study drug. Men who partner with a woman of childbearing&#xD;
             potential, unless they agree to use effective contraception while on study drug&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840007</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0542</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840005</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840006</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840008</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056001</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 056002</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2013</study_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

